NCT04293562 2026-02-24
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Children's Oncology Group
Phase 3 Recruiting
Children's Oncology Group
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Baylor College of Medicine
Children's Hospital of Soochow University